[A19-36] Nintedanib (idiopathic pulmonary fibrosis) - Benefit assessment according to §35a Social Code Book V
Last updated 15.07.2019
Project no.:
A19-36
Commission:
Commission awarded on 11.04.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system
Adults with idiopathic pulmonary fibrosis
The disadvantage regarding the side effects (gastrointestinal disorders) does not completely call into question the advantage in exacerbations; proof of a minor added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A19-64 | Nintedanib (idiopathic pulmonary fibrosis) - Addendum to Commission A19-36 | Commission completed |
| A15-01 | Nintedanib - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| G15-03 | Nintedanib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A20-70 | Nintedanib (systemic sclerosis associated interstitial lung disease in adults) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-71 | Nintedanib (interstitial lung disease) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-10-17 A G-BA decision was published.